Skip to main content

INKREDIBLE by CELLINK

HardwareGothenburg, SwedenFounded 2016· One of 1739 Hardware companies tracked by AMPulse

Develops 3D bioprinters and bioinks for tissue engineering and drug discovery, enabling the creation of 3D biological structures like skin and bone.

CEO / Founder
Stefan Blomsterberg
Team Size
201-500
Stage
Active
Total Funding
$153.3M
Latest Round
Post-IPO
Key Investors
Handelsbanken Funds, Nasdaq First North public investors

Technology & Products

Key Products

INKREDIBLE+, BIO X, CELLINK GO

Technological Advantage

Proprietary extrusion-based bioprinting using bioinks that mimic natural cellular environments; integration of acquired technologies like Prellis Biologics' Holograph-X.

Differentiation

Value Proposition

First company to offer commercial bioinks globally, providing a full ecosystem of extrusion-based bioprinters and patented materials that mimic natural cellular environments.

How They Differentiate

Offers the only true benchtop bioprinter (INKREDIBLE+) and a comprehensive range from educational (CELLINK GO) to high-end research systems (BIO X).

Market & Competition

Target Customers

Research laboratories at institutions like Harvard and MIT, pharmaceutical companies, and the cosmetics industry.

Industry Verticals

Pharmaceutical R&D; Drug Discovery; Cosmetics; Medical Research; Tissue Engineering; Organ Modeling

Competitors

RegenHU; 3D Systems (Allevi); Aspect Biosystems

Growth & Milestones

Growth Metrics

Net turnover grew 245% YoY to SEK 45.3M in 2018; Operating revenues grew 196% YoY to SEK 64.4M; Over 200% annual growth stated in 2018.

Major Milestones

Founded January 27, 2016; IPO on Nasdaq First North November 3, 2016; BIO X won Red Dot Award April 2018; Launched CELLINK GO May 2, 2018; Rebranded as BICO August 2021

Notable Customers

Harvard; MIT; FDA; Newcastle University; CTIBIOTECH; AstraZeneca; Takara Bio; Kyoto University

http://www.cellink.com

Why this company matters

CELLINK, now part of BICO Group, established itself as the first commercial provider of bioinks, filling a gap between academic lab-scale bioprinting and reproducible, off-the-shelf materials. Its core technology is material extrusion (MEX) bioprinting, using proprietary bioinks that mimic natural cellular environments to create 3D biological structures such as skin and bone models.

The company's product line spans from the educational CELLINK GO to the benchtop INKREDIBLE+ and the high-end BIO X system, which won a Red Dot Award in 2018. These systems serve pharmaceutical R&D, drug discovery, cosmetics testing, and medical research. Named customers include Harvard, MIT, the FDA, AstraZeneca, and Kyoto University.

CELLINK's strategic moat lies in its integrated hardware-and-bioink ecosystem and rapid go-to-market: it went public on Nasdaq First North just 10 months after its 2016 founding. The company maintains dual headquarters in Sweden and the US to stay close to top research hubs. Key partnerships with Chalmers University, MIT, and AstraZeneca BioVentureHub reinforce its position, though it faces competition from RegenHU, 3D Systems (Allevi), and Aspect Biosystems in the growing bioprinting market.